Literature DB >> 1827688

Arginine-specific suppression of mixed lymphocyte culture reactivity by Kupffer cells--a basis of portal venous tolerance.

M P Callery1, M J Mangino, M W Flye.   

Abstract

Portal venous administration of alloantigen abrogates the DTH response and prolongs heart and kidney allograft survival. Within the hepatic microenvironment, negligible L-arginine levels result from the effects of the highest tissue arginase activity of any organ (25 times greater than kidney). This study evaluated the effects of arginine availability on Kupffer cell immune function in the rat mixed lymphocyte culture. When 5 x 10(5) Wistar-Furth unfractionated lymph node cells (LNC) were cultured with 5 x 10(5) irradiated Lewis LNC in standard RPMI-1640 medium containing 1200 microM L-arginine, the proliferative response was not effected by the addition of 1 x 10(5) WF KC. However, when L-arginine-depleted medium (6 microM) was used, the MLC response was markedly reduced by the addition of KC. This was specific to arginine since media depletion of L-lysine, a similar basic amino acid, did not affect MLC/KC responses. When syngeneic WF KC were added as antigen-presenting cells to fractionated stimulator and responder T lymphocytes, WF/LEW MLC proliferation was restored in standard and L-lysine-depleted media, but did not increase in L-arginine-depleted RPMI 1640 medium. These responses correlated with a fivefold increase in KC prostaglandin-E2 (PGE2) production in the L-arginine-depleted medium. These findings support the hypothesis that diminished immune responsiveness in the low-arginine hepatic environment is effected, at least in part, by locally increased production of the immunosuppressant prostaglandin-E2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827688     DOI: 10.1097/00007890-199105000-00028

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

Review 2.  Liver antigen-presenting cells.

Authors:  Ian Nicholas Crispe
Journal:  J Hepatol       Date:  2010-10-16       Impact factor: 25.083

3.  In vitro toxicity assessment of amphiphillic polymer-coated CdSe/ZnS quantum dots in two human liver cell models.

Authors:  Wesley E Smith; Jessica Brownell; Collin C White; Zahra Afsharinejad; Jesse Tsai; Xiaoge Hu; Stephen J Polyak; Xiaohu Gao; Terrance J Kavanagh; David L Eaton
Journal:  ACS Nano       Date:  2012-10-18       Impact factor: 15.881

Review 4.  O death where is thy sting? Immunologic tolerance to apoptotic self.

Authors:  Buvana Ravishankar; Tracy L McGaha
Journal:  Cell Mol Life Sci       Date:  2013-02-03       Impact factor: 9.261

5.  Immune tolerance in liver disease.

Authors:  Ian N Crispe
Journal:  Hepatology       Date:  2014-09-26       Impact factor: 17.425

Review 6.  Immune-Mediated Therapies for Liver Cancer.

Authors:  Rajagopal N Aravalli; Clifford J Steer
Journal:  Genes (Basel)       Date:  2017-02-17       Impact factor: 4.096

7.  Recovery from mouse hepatitis virus infection depends on recruitment of CD8(+) cells rather than activation of intrahepatic CD4(+)alphabeta(-)TCR(inter) or NK-T cells.

Authors:  L Lamontagne; S Lusignan; C Page
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

Review 8.  The Liver-Immunity Nexus and Cancer Immunotherapy.

Authors:  James C Lee; Michael D Green; Laura A Huppert; Christine Chow; Robert H Pierce; Adil I Daud
Journal:  Clin Cancer Res       Date:  2021-07-20       Impact factor: 12.531

9.  Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair.

Authors:  Anat London; Merav Cohen; Michal Schwartz
Journal:  Front Cell Neurosci       Date:  2013-04-08       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.